MONTREAL, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leader in healthcare services and technologies, is pleased to announce that its wholly-owned subsidiary, Cambridge based Canadian Health Care Agency (“CHCA”), has been retained as a primary contractor for 4-year contracts with Indigenous Services Canada (“ISC”).
CHCA has been retained as a primary contractor in Ontario, and as back-up stream in Manitoba and Alberta, to provide nursing services and care primarily in remote, isolated, and semi-isolated communities. The contracts have an initial term of 4 years, for an initial estimated value of $23.4M and includes 4 1-year extension options, that if exercised, could increase the total value of the contracts over the full 8-year period. The contracts were awarded on November 3 and are to transition in early 2024. Indigenous Services Canada (ISC) works collaboratively with partners to improve access to high quality services for First Nations, Inuit, and Métis. ISC’s vision is to support and empower Indigenous people to independently deliver and address the socio-economic conditions in their communities.
CHCA is a provider of specialized nursing services that focuses on the recruitment, training, and placement of Registered Nurses and Nurse Practitioners for expanded roles and essential services to Indigenous communities across Canada’s north. CHCA is based in Cambridge, Ontario, and was founded in 2001 in response to severe staffing shortages in Canada’s northern regions.
“We are pleased to have been selected to continue working with ISC. Our exceptional health care and administrative professionals are excited about the contract award, and appreciate the trust placed in CHCA to continue providing health care services to remote, isolated, and semi-isolated First Nations communities in ON, MB, and AB.” said Giovanni Garay, general manager of CHCA.
About Premier Health
Premier Health is a leading Canadian Healthtech company that provides a comprehensive range of outsourced services solutions for healthcare needs to governments, corporations, and individuals. Premier Health uses its proprietary LiPHe® platform to lead the healthcare services sector digital transformation to provide patients with faster, cheaper, and more accessible care services.
For Further Information Please Contact:
Mr. Jean-Robert Pronovost
Vice President Business Development
Premier Health of America Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it. / 1 800 231 9916
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This press release contains forward-looking information within the meaning of applicable securities legislation which reflects the current plans and expectations of the Corporation with respect to future events and financial performance. All statements other than statements of historical or current facts may be forward-looking information. Forward-looking information includes statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as ‘believes’, ‘continues’, ‘expects’, ‘projects’, ‘anticipates’, ‘plans’, ‘estimates’, ‘seeks’, ‘intends’, ‘targets’, ‘forecasts’, or negative or grammatical versions thereof and other similar expressions, or future or conditional verbs such as ‘may’, ‘will’, ‘should’, ‘would’ and ‘could’. Forward-looking information in this press release includes, but is not limited to, statements with respect to the execution of the Corporation’s growth strategy. Forward-looking information is based on management’s plans, estimates, projections, beliefs and opinions as at the date of this release, and the assumptions related to those plans, estimates, projections, beliefs and opinions may change; therefore, they are presented for the purpose of assisting the Corporation’s security holders in understanding management’s views at such time regarding those future outcomes and may not be appropriate for other purposes. Although the forward-looking information contained in this release is based on assumptions which the Corporation believes are reasonable, there can be no assurance that actual results will be consistent with such forward-looking information. The forward-looking information in this release relate only to events or information as of the date on which the statements are made and, except as specifically required by applicable securities laws, the Corporation undertakes no obligation to update or revise publicly any forward-looking information, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. There can be no assurance that the forward-looking information will prove to be accurate. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. The Corporation assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. These factors and others are more fully discussed in the filings of the Corporation with Canadian securities regulatory authorities available at www.sedarplus.ca
Last Trade: | C$0.14 |
Daily Change: | -0.02 -9.68 |
Daily Volume: | 13,500 |
Market Cap: | C$7.770M |
December 10, 2024 November 14, 2024 August 21, 2024 May 23, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB